Catatonia Catatonia is the least recognized movement disorder associated with antipsychotic drugs. Neuroleptic malignant syndrome NMS represents an extremely rare but potentially lethal form of EPS combining features of advanced parkinsonism and catatonia. Tardive dyskinesia In contrast to acute EPS, TD is insidious in onset, arises only after prolonged treatment and is often masked by ongoing treatment. Figure 1. Footnotes Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. References 1. Preskorn SH. The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol.
J Psychiatr Pract. Rifkin A. Extrapyramidal side effects: a historical perspective. J Clin Psychiatry. Van Putten T.
The authors provide an overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) sponsored by the National Institute of. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol.
Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry. Caroff S.
The Neuroleptic malignant syndrome. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. The Seroquel Trial 13 Study Group. Biol Psychiatry. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Am J Psychiatry. Risperidone in the treatment of schizophrenia. Ziprasidone Study Group. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes IC-SOHO study. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
Movement disorders associated with atypical antipsychotic drugs. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res.
Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. A meta-analysis of the efficacy of second-generation antipsychotics. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
N Engl J Med. Extrapyramidal side-effects of antipsychotics in a randomised trial.
Br J Psychiatry. Cambridge: Cambridge University Press; A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation.
Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol. Acute dystonia induced by drug treatment. Acute dystonia induced by neuroleptic drugs. Psychopharmacology Berl ; 88 4 — Tarsy D, Simon DK. The dystonias. Nemeth AH.
The genetics of primary dystonias and related disorders. Prediction of neuroleptic-induced dystonia. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Extrapyramidal symptoms in patients treated with risperidone. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia.
Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother. The pathophysiology of primary dystonia. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people.
Postgrad Med J. The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. J Neurol. Jul 16; [ PubMed ].
Gelenberg AJ. General principles of treatment of extrapyramidal syndromes. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. A week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry Suppl. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. Treating extrapyramidal reactions: some current issues.
Bras JM, Singleton A. Biochim Biophys Acta. Akathisia: an updated review focusing on second-generation antipsychotics. Chronic restlessness with antipsychotics. Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Feb; 2 — Barnes TR. A rating scale for drug-induced akathisia.